Both PD1/PD-L1 antibodies showed promising efficacy in Hodgkin lymphoma and some solid tumours, but their clinical application in NKTCL needs to be further explored. This evidence concerns the gene PDCD1 and extranodal nasal NK/T cell lymphoma.